Table 4 Change of adiposity markers during follow-up by use of specific antidepressants during follow-up.

From: Long-term changes in adiposity markers during and after antidepressant therapy in a community cohort

 

Change in adiposity markers during follow-up

Body Mass Index [kg/m2] (n = 2462)

Waist circumference [cm] (n = 2475)

Fat mass [%] (n = 2079)

βa

(95%CI)

βa

(95%CI)

βa

(95%CI)

TCA

 Clomipramine

−0.38

(−1.30, 0.53)

0.44

(−3.29, 4.17)

−0.94

(−3.49, 1.61)

 Amitriptyline

0.10

(−0.54, 0.74)

1.63

(−1.10, 4.37)

−0.37

(−2.19, 1.45)

 Melitracen and psycholeptics

0.41

(−0.33, 1.16)

1.70

(−1.48, 4.87)

0.33

(−1.98, 2.64)

SSRI

 Fluoxetine

0.37*

(0.02, 0.72)

1.88*

(0.40, 3.36)

1.54**

(0.49, 2.58)

 Citalopram

−0.16

(−0.50, 0.19)

−0.33

(−1.79, 1.13)

−0.35

(−1.43, 0.73)

 Paroxetine

−0.02

(−0.49, 0.44)

−0.69

(−2.67, 1.29)

0.81

(−0.63, 2.24)

 Sertraline

0.65*

(0.13, 1.16)

1.23

(−0.96, 3.41)

1.36

(−0.18, 2.90)

 Escitalopram

0.55***

(0.23, 0.87)

1.95**

(0.57, 3.33)

0.64

(−0.38, 1.65)

Mirtazapine/Trazodone

 Mirtazapine

−0.26

(−0.79, 0.27)

−1.18

(−3.44, 1.09)

0.34

(−1.39, 2.07)

 Trazodone

0.36

(−0.36, 1.07)

1.53

(−1.54, 4.60)

−0.63

(−2.76, 1.50)

SNRI

 Venlafaxine

0.24

(−0.18, 0.67)

0.83

(−0.99, 2.65)

−0.50

(−1.73, 0.73)

 Duloxetine

0.24

(−0.28, 0.75)

0.90

(−1.32, 3.12)

−0.57

(−2.06, 0.92)

No antidepressants (ref.)

0 (ref.)

—

0 (ref.)

—

0 (ref.)

—

  1. TCA tricyclic antidepressants, SSRI selective serotonin reuptake inhibitors, SNRI serotonin-noradrenaline reuptake inhibitors, 95%CI 95% confidence interval. ref. reference group.
  2. aAdjusted for socio-demographic characteristics (sex, age, socio-economic status, living alone during follow-up), early physical and sexual abuse, adiposity marker levels at baseline, behavioral factors (physical inactivity, smoking status, number of drinks per week) during follow-up, anxiety disorders and illicit drug dependence during follow-up, possibly weight gain inducing medication (other than antidepressants) during follow-up, length of follow-up, major depressive disorder (MDD) subtypes at baseline and during follow-up and current vs. remitted MDD status at follow-up, severity during follow-up (number of symptoms of most severe major depressive episode (MDE), time spent in MDE, global assessment functioning (GAF) score, suicidality, hospitalization, psychotic features), relatives with MDD, number of different antidepressant compounds prior to baseline, and other antidepressants (Fluvoxamine, Bupropion, Reboxetine, Moclobémide, Trimipramine, Mianserin) during follow-up.
  3. * p < 0.05, ** p < 0.01, *** p < 0.001.
  4. Significant results are indicated in bold.
Back to article page